RSV Vaccine Eligibility Expands - Top-Institutions - MDSpire

RSV Vaccine Eligibility Expands

Trial data show noninferior immune response in high-risk adults aged 18 to 49 years.

  • By

  • Kathryn Wighton

  • March 13, 2026

  • 3 min

Share

Top Institutions in Infectious Disease

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID)
    National Institute of Allergy and Infectious Diseases (NIAID)

    Bethesda, MD

    Key Differentiators

    • Infectious Diseases
    • Vaccine Development
    • Immunology

  • #2

    Vanderbilt University Medical Center
    Vanderbilt University Medical Center

    Nashville, TN

    Key Differentiators

    • Infectious Diseases
    • Pulmonology
    • Vaccine Research

  • #3

    Johns Hopkins University School of Medicine
    Johns Hopkins University School of Medicine

    Baltimore, MD

    Key Differentiators

    • Infectious Diseases
    • Pulmonary Medicine
    • Vaccine Development

  • #4

    University of Rochester Medical Center
    University of Rochester Medical Center

    Rochester, NY

    Key Differentiators

    • Infectious Diseases
    • Immunology
    • Clinical Trials

  • #5

    Centers for Disease Control and Prevention (CDC)
    Centers for Disease Control and Prevention (CDC)

    Atlanta, GA

    Key Differentiators

    • Epidemiology
    • Infectious Diseases
    • Public Health

Original Source(s)

RSV Vaccine Eligibility Expands

  • by Kathryn Wighton

  • March 13, 2026

Related Content

Ensitrelvir Reduced COVID After Household Exposure

In SCORPIO-PEP, symptomatic COVID-19 occurred in 3% vs 9% of household contacts by day 10.

Age and hypoalbuminemia independently predict pulmonary consolidation in children with 23S rRNA A2063G-mutant Mycoplasma pneumoniae pneumonia: a retrospective single-center study

Manufacturability is access: redesigning antibody production for equitable pediatric access in LMICs